Skip to main content
. 2023 May 2;6(5):e2311181. doi: 10.1001/jamanetworkopen.2023.11181

Figure 1. Study Flow Diagram Showing Cohort Selection.

Figure 1.

The final evaluable 674 patient cohort was further stratified into prospective (immune checkpoint inhibitors [ICIs] received after tumor mutational burden testing) and retrospective patients (ICIs received before tumor mutational burden testing; see Methods section). CGP indicates comprehensive genomic profiling.